Fig. 4

Model 2 for differentiating fibrosis vs. cirrhosis and model 3 for differentiating early fibrosis vs. advanced fibrosis in CLD patients with chronic HBV infection. a ROC curves of model 2 (RF model constructed with four metabolite markers and age), APRI, AST/ALT, and FIB-4 in cohort 1. b PR curves of model 2, APRI, AST/ALT, and FIB-4 in cohort 1. c ROC curves for model 2, APRI, AST/ALT, and FIB-4 for the cohort 2 validation set. d PR curves for model 2, APRI, AST/ALT, and FIB-4 for the cohort 2 validation set. e The RF score in CLD patients with fibrosis and cirrhosis in the HBV training, validation sets. The optimal cutoff value of the RF score was 0.01. f ROC curves of model 3 (RF model constructed with four metabolite markers and age), APRI, AST/ALT, and FIB-4 in cohort 1. g PR curves of model 3, APRI, AST/ALT, and FIB-4 in cohort 1. h ROC curves for model 3, APRI, AST/ALT, and FIB-4 for the cohort 2 validation set. i PR curves for model 3, APRI, AST/ALT, and FIB-4 for the cohort 2 validation set. j The RF score in CLD patients with S0–2 and S3–4 in the HBV training, validation sets. The optimal cutoff value of the RF score was − 0.115. ***p < 0.001, Wilcoxon’s rank-sum test